Dare Bioscience (DARE) Expected to Post Earnings on Thursday

Dare Bioscience (NASDAQ:DARE) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Dare Bioscience to post earnings of ($0.1267) per share and revenue of $2.04 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.10. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.00 million. On average, analysts expect Dare Bioscience to post ($0.74) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

Dare Bioscience Stock Up 1.8%

Dare Bioscience stock opened at $0.66 on Thursday. The firm has a fifty day moving average of $0.74 and a 200-day moving average of $1.55. Dare Bioscience has a 52-week low of $0.62 and a 52-week high of $3.78. The firm has a market capitalization of $13.02 million, a P/E ratio of -0.95 and a beta of 1.11.

Wall Street Analyst Weigh In

DARE has been the subject of a number of research reports. Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. UBS Group set a $1.00 price objective on Dare Bioscience in a research report on Monday, September 14th. Weiss Ratings cut Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. LADENBURG THALM/SH SH began coverage on Dare Bioscience in a research report on Monday, October 26th. They issued a “buy” rating and a $2.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dare Bioscience presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Dare Bioscience Company Profile

Daré Bioscience, Inc (NASDAQ: DARE) is a biopharmaceutical company focused on developing and commercializing therapies designed to address unmet needs in women’s health. The company’s research and development activities span contraception, vaginal health, sexual health and reproductive health, with an emphasis on pharmaceutical products and drug-delivery technologies.

Daré’s lead commercial product is XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved prescription treatment for bacterial vaginosis in females 12 and older.